Articles from March 2013
Posted by Site Administrator on March 28, 2013
TORONTO, Canada, March 20, 2013 /CNW/ — Amorfix Life Sciences announced today that it has furthered the development of the first effective blood test to diagnose amyotrophic lateral sclerosis (ALS) by cloning ultra-high affinity antibodies that detect a misfolded version of the enzyme superoxide dismutase 1 (SOD1), which has been implicated in the development of [...]
Categories: ALS Community News, ALS News, Research News, Treatments
| 
Tags: ALS, ALS community, ALS diagnosis, ALS diagnostics, ALS research, ALS research funding, ALS therapeutic antibodies, ALS treatments, ALS vaccines, Amorfix Life Sciences, amyotrophic lateral sclerosis, blood test ALS, Bob Stehlin, Dr. Neil Cashman, Dr. Robert Gundel, PALS, Pan-Provincial Vaccine Enterprise Inc. (PREVENT), RASCALS Foundation, Robert A. Stehlin Campaign for ALS, SOD1, SOD1 ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis
| 
No comments
Posted by Site Administrator on March 26, 2013
Data Indicate Initial Clinical Benefit in Overall Clinical and Respiratory Function
NEW YORK, NY and PETACH TIKVAH, ISRAEL, March 21, 2013 — BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, today reported some of the final results from a clinical study evaluating the company’s NurOwn™ technology in 12 ALS patients. NurOwn [...]
Categories: ALS News, Clinical Trials, Research News, Technology, Treatments
| Tags: Alon Natanson, ALS, ALS community, ALS cure, ALS medical care, ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, Analysis of 12 Patients with Amyotrophic Lateral Sclerosis (ALS) Treated with Autologous Differentiated Mesenchymal Stem Cells: a Phase I/II Clinical Trial, Annual Meeting of the American Academy of Neurology, Bob Stehlin, BrainStorm Cell Therapeutics, Brainstorm Cell Therapeutics Inc., Dimitrios Karussis, Hadassah Medical Center, Mesenchymal Stem Cells ALS, MSC-NTF ALS, NurOwn, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis
| No comments
Posted by Site Administrator on March 25, 2013
“This innovative diaphragm pacing system is an exciting development in the treatment of ALS. It has the potential to improve and extend the lives of hundreds of ALS patients. It is thrilling that our BWH team is able to bring this new treatment to ALS patients in New England,” said Dr. Ducko.
Categories: ALS Community News, ALS Families, ALS News, Research News, Technology
| Tags: ALS, ALS community, ALS medical care, ALS research, amyotrophic lateral sclerosis, Bob Stehlin, Brigham and Women’s Hospital (BWH), diaphragm pacing system, Dr. Christopher Ducko, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, Scott Murphy, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Stem cells ALS
| No comments
Posted by Site Administrator on March 25, 2013
At a time when scientists are making rapid gains in the genetic roots of many diseases, Mr. Doctoroff, a former deputy mayor and private equity investor, is working with Mayor Michael R. Bloomberg and a private equity director, David M. Rubenstein, to put together a $25 million package of donations to support research to try to cure this rare and usually fatal degenerative neurological illness.
Categories: ALS Community News, ALS News, Research News
| Tags: A.L.S. Association, ALS, ALS community, ALS cure, ALS medical care, ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, Bloomberg L.P., Bloomberg Philanthropies, Bob Stehlin, C9ORF72, Carlyle Group, Columbia University, Daniel L. Doctoroff, David M. Rubenstein, Franklin & Marshall College, Johns Hopkins, Lou Gehrig's disease, Martin Doctoroff, Mayor Michael R. Bloomberg, PALS, Patricia E. Harris, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Target A.L.S.
| No comments
Posted by Site Administrator on March 20, 2013
Mouse engineers presented the latest models overexpressing the amyotrophic lateral sclerosis gene fused in sarcoma (FUS) at “New Frontiers in Neurodegenerative Disease Research,” a Keystone Symposium held 4-7 February 2013 in Santa Fe, New Mexico. These animals have been four years in the making. This is a long time even for mice (see ARF related [...]
Categories: ALS News, Research News, Technology
| Tags: ALS, ALS arginine-514-guanine, ALS community, ALS FUS transgenic mice, ALS gene fused in sarcoma (FUS), ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, arginine-521-cysteine (R521C) mutation ALS, Dr. Udai Pandey, FUS transgene ALS, Gladstone Institutes in San Francisco., huntingtin, Lou Gehrig's disease, Louisiana State University Health Sciences Center in New Orleans, New Frontiers in Neurodegenerative Disease Research, PALS, progressive motor neuron disease, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Steven Finkbeiner, superoxide dismutase 1 (SOD1), TDP-43
| No comments
Posted by Site Administrator on March 20, 2013
SPF/NEALS Fellowship Grant intended to further cutting-edge research into ALS’s little-known cousin, Primary Lateral Sclerosis (PLS).
COLUMBUS, Ohio, February 21, 2013 — (24-7PressRelease) The Spastic Paraplegia Foundation (SPF) and the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) have announced the first Virginia Freer-Sweeney Clinical Research Training Fellowship in primary lateral sclerosis (PLS). The fellowship highlights another successful [...]
Categories: Research News
| Tags: ALS community, ALS research, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, Lou Gehrig's disease, Northeast Amyotrophic Lateral Sclerosis Consortium, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, The Spastic Paraplegia Foundation (SPF)
| No comments
Posted by Site Administrator on March 20, 2013
MDA has awarded a $400,000 grant to National Institutes of Health (NIH) Laboratory of Neurogenetics researchers to perform exome sequencing on samples taken from 1,000 people with sporadic amyotrophic lateral sclerosis (ALS). The project will be led by neurologist Bryan Traynor, head of the Neuromuscular Diseases Research Group at the NIH in Bethesda, Md.
Categories: ALS News, Research News, Technology, Treatments, Uncategorized
| Tags: ALS, ALS community, ALS diagnosis, ALS diagnostics, ALS research, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, Coriell ALS Repository., DNA ALS, exome sequencing ALS, Lou Gehrig's disease, MDA translational research program, MDA Vice President of Research Jane Larkindale, Muscular Dystrophy Association MDA, National Institutes of Health (NIH), National Institutes of Health Laboratory of Neurogenetics, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, whole genome sequencing ALS
| No comments
Posted by Site Administrator on March 7, 2013
Daniel L. Doctoroff, chief executive officer and president of Bloomberg LP; David M. Rubenstein, co-CEO of The Carlyle Group; and Bloomberg Philanthropies said Target ALS is a $25 million three-year initiative to tackle ALS in a different way.
Categories: ALS News, Research News, Treatments
| Tags: 501(c)(3) ALS charity, ALS community, ALS medical care, ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, Bloomberg LP, Bloomberg Philanthropies, Bob Stehlin, Daniel L. Doctoroff, David M. Rubenstein, Lou Gehrig's disease, Michael R. Bloomberg, PALS, Project A.L.S., RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Target ALS, The Carlyle Group
| No comments
Posted by Site Administrator on March 7, 2013
A new study in the current issue of STEM CELLS Translational Medicine demonstrates how human stem cells can successfully engraft, survive and differentiate into mature neurons in the spinal cord of a rat with amyotrophic lateral sclerosis (ALS). The results offer new hope for those suffering from this disease, which generally ends in death within three to five years after diagnoses.
Categories: ALS News, Research News, Treatments
| Tags: Hannover Medical School in Germany, induced pluripotent stem cells (iPSCs), INSERM et Université Paris-Sud, Pasteur Institute, Roland Pochet, STEM CELLS Translational Medicine, transplantation of stem-cell ALS, Université libre de Bruxelles
| No comments
Posted by Site Administrator on March 7, 2013
“In identifying the novel protein that abnormally accumulates in the brains of affected patients, we have uncovered a potentially new therapeutic target and biomarker that would allow clinicians to confirm diagnosis of the diseases,” says senior author Dr. Leonard Petrucelli, Chair of Neuroscience at Mayo Clinic in Florida.
Categories: ALS News, Research News, Treatments
| Tags: ALS, ALS community, ALS diagnosis, ALS diagnostics, ALS medical care, ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, C9ORF72, C9ORF72 gene, C9RANT, Dr. Leonard Petrucelli, Neuroscience at Mayo Clinic in Florida, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis
| No comments
